DeuteRx deuterx.com


Public list: Pharma Startups (6570) Cancer Therapeutics (1180) Neuroscience Startups (947)

DeuteRx is focused on 'deuterium-enabled chiral switching' (DECS), an approach to improve racemic (a mixture of two mirror-image compounds or enantiomers) small molecule marketed drugs and drug candidates intended for patients across multiple therapeutic indications. Numerous drugs are still developed and marketed as racemic mixtures because the enantiomers are chemically unstable and rapidly interconvert in vivo. To date, DeuteRx has demonstrated the use of DECS to stabilize the enantiomers of ...Show all

DeuteRx is focused on 'deuterium-enabled chiral switching' (DECS), an approach to improve racemic (a mixture of two mirror-image compounds or enantiomers) small molecule marketed drugs and drug candidates intended for patients across multiple therape...Show all

Company (Alive / Active)

Phone: 978-662-5287

Fax:

300 Brickstone Square
Suite 201
Andover, 01810
Massachusetts, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
DeuteRx $2.8M Sep 30, 2015

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related DeuteRx Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 1 investors
There is no Board of Directors data available for this company. Please select another tab.
There is no Competitors data available for this company. Please select another tab.